New PET tracer could spot hidden cancers
NCT ID NCT04459273
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can help detect and understand different cancers better than current methods.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Gallium Ga 68 FAPi-46 (a radioactive tracer for PET scans)
- What this could lead to
- If successful, this could lead to a new imaging method to better detect and understand many types of cancer, potentially improving diagnosis and treatment planning.
- What could go wrong
- This is a very early, small study (26 people) focused on imaging, not treatment. The tracer may not work well for all cancers, and results may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
26 people
The number who actually took part.
- Started
-
Aug 2020
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with the following cancer types: * Brain cancer * Bladder cancer * Urothelial cancer * Testicular cancer * Skin cancer * Thyroid cancer * Hepatocellular carcinoma * Cholangiocarcinoma * Thymus cancer * Pleural cancer * Cervical cancer * Adrenal cancer * Neuroendocrine tumors * Hematologic cancer * Cancer of Unkown Primary * Patients who are scheduled to undergo surgical resection or tissue biopsy of the primary tumor and/or metastasis * Patients are ≥ 18 years old at the time of the radiotracer administration. * Patient can provide written informed consent * Patient is able to remain still for duration of imaging procedure (up to one hour) Exclusion Criteria: * Patient is pregnant or nursing * Patients with any new cancer therapy between the baseline PET/CT and the investigational FAPI PET/CT * Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bladder carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sparing the liver: targeted chemoembolization meets lenvatinib in liver cancer
- Can intensified chemotherapy before surgery clear bladder tumors?
- AI-Enhanced ultrasound aims to catch liver cancer earlier
- Can turbocharged immune cells stop liver cancer from coming back?
- Chemo combo tested as backup for bladder cancer that outsmarts First-Line therapy
- Two blood markers put to the test for early liver cancer detection